Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 6/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5778979 | 0.91 | CRHR1 (0.43) | CRHR1HCRTR1 | |
| SCHEMBL6081266 | 0.90 | CRHR1 (0.43) | CRHR1HCRTR1 | |
| SCHEMBL6080856 | 0.90 | CRHR1 (0.43) | CRHR1HCRTR1 | |
| SCHEMBL6081770 | 0.88 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL5431322 | 0.86 | CRHR1 (0.42) | CRHR1 | |
| SCHEMBL6082161 | 0.86 | CRHR1 (0.42) | CRHR1 | |
| SCHEMBL6080964 | 0.86 | CRHR1 (0.44) | CRHR1 | |
| SCHEMBL5778772 | 0.85 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL6507897 | 0.83 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL5782147 | 0.82 | CRHR1 (0.47) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113379-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | AVENTIS PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | claimed |
| US-20060199823-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | NEUROGEN CORPORATION (US) | 2006-09-07 | — | — | US | disclosed |
| US-20050113379-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | AVENTIS PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199823-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | CRHR1, CRHR2, HTR5A | CRHR1 1/4885HCRTR1 31/4885HCRTR2 41/4885 |
| US-20050113379-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | CRHR1, CRHR2, HTR5A | CRHR1 1/4885HCRTR1 31/4885HCRTR2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.